The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double‐blind, placebo‐controlled, multicenter study
HA Hanagasi, H Gurvit, P Unsalan… - Movement …, 2011 - Wiley Online Library
Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a
selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic
transmission. Dopamine is thought to be involved in certain cognitive processes such as
working memory. We assessed the effects of rasagiline on cognitive deficits in cognitively
impaired, nondemented patients with Parkinson's disease. This was a randomized, double‐
blind, placebo‐controlled prospective study. Patients with Parkinson's disease receiving …
selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic
transmission. Dopamine is thought to be involved in certain cognitive processes such as
working memory. We assessed the effects of rasagiline on cognitive deficits in cognitively
impaired, nondemented patients with Parkinson's disease. This was a randomized, double‐
blind, placebo‐controlled prospective study. Patients with Parkinson's disease receiving …
[引用][C] The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter …
HA Hanagasi - Movement Disorders: Official Journal of the …, 2015 - europepmc.org
… Citations & impact … This article has not been cited yet. Impact metrics …
以上显示的是最相近的搜索结果。 查看全部搜索结果